Dernières nouvelles pour Exact Sciences (NASDAQ:EXAS) Stock

Exact Sciences

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.

Exact Sciences Corporation - Common Stock

Exact Sciences Corp

Citigroup analyst Patrick Donnelly maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $80 to $75.

News

Price Target

Analyst Ratings

EXAS

Citigroup Maintains Buy on Exact Sciences, Lowers Price Target to $75

Jefferies analyst Brandon Couillard maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and raises the price target from $84 to $85.

Jefferies Maintains Buy on Exact Sciences, Raises Price Target to $85

BTIG analyst Mark Massaro maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $82 to $65.

BTIG Maintains Buy on Exact Sciences, Lowers Price Target to $65

Stifel analyst Daniel Arias maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $82 to $67.

Stifel Maintains Buy on Exact Sciences, Lowers Price Target to $67

Canaccord Genuity analyst Kyle Mikson maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $95 to $75.

Canaccord Genuity Maintains Buy on Exact Sciences, Lowers Price Target to $75

TD Cowen analyst Dan Brennan maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $90 to $82.

TD Cowen Maintains Buy on Exact Sciences, Lowers Price Target to $82

Goldman Sachs analyst Matthew Sykes maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $75 to $65.

Goldman Sachs Maintains Buy on Exact Sciences, Lowers Price Target to $65

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock moved upwards by 77.9% to $7.49 during Wednesday's regular session. The company's market cap stands at $38.9 million. </li>
<li>Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares moved upwards by 29.22% to $7.03. The company's market cap stands at $924.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) stock increased by 23.78% to $7.13. The market value of their outstanding shares is at $443.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares moved upwards by 21.63% to $2.98. The company's market cap stands at $104.0 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock moved upwards by 21.26% to $0.34. The market value of their outstanding shares is at $10.5 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock increased by 16.24% to $5.94. The company's market cap stands at $108.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) stock declined by 39.6% to $3.13 during Wednesday's regular session. The company's market cap stands at $335.3 million. As per the press release, Q3 earnings came out today. </li>
<li>PACS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares decreased by 39.39% to $17.91. The market value of their outstanding shares is at $2.7 billion. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock declined by 31.98% to $0.09. The market value of their outstanding shares is at $1.5 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares declined by 31.5% to $1.74. The market value of their outstanding shares is at $1.8 million. </li>
<li>Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock decreased by 27.36% to $51.95. The company's market cap stands at $9.5 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) stock decreased by 22.71% to $88.86. The market value of their outstanding shares is at $6.1 billion. As per the news, the Q3 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BJDX

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CTKB

LNTH

OPRX

PACS

RAPT

SONN

TMCI

TNGX

ZVSA

12 Health Care Stocks Moving In Wednesday's Intraday Session

Evercore ISI Group analyst Vijay Kumar maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Outperform and lowers the price target from $80 to $60.

Evercore ISI Group Maintains Outperform on Exact Sciences, Lowers Price Target to $60

On Tuesday, Exact Sciences Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss estimate of $0.20.</a>
The reported quarterly sales of $708.66 million missed the consensus <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41757648/exact-sciences-announces-third-quarter-2024-results" rel="noreferrer noopener">estimate of $717.66 million</a>.
Screening revenue was $545 million, an increase of 15%, and Precision Oncology&#8217;s revenue was $164 million, an increase of 5% on a reported and core revenue basis.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41185292/fda-clears-exact-sciences-next-generation-colorectal-cancer-diagnostic-test" rel="noreferrer noopener">FDA Clears Exact Sciences&#8217; Next-Generation Colorectal Cancer Diagnostic Test</a>.
&#8220;While we have made progress, our execution during the third quarter and updated outlook for the full year don&#8217;t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong,&#8221; said Kevin Conroy, chairman and CEO.
Guidance: Exact Sciences cuts its 2024 revenue guidance from $2.81 billion-$2.85 billion to $2.73 billion-$2.75 billion compared to the consensus of $2.832 billion.
The guidance includes a Screening sales forecast of $2.08 billion—$2.095 billion, compared to previous guidance of $2.155 billion—$2.175 billion.
Precision Oncology sales are expected to be $650 million- $655 million, down from prior guidance of $655 million &#8211; $675 million.
The company expects 2024 Adjusted EBITDA of $310 million—$320 million, down from previous guidance of $335 million—$355 million.
William Blair notes that management attributed the lower-than-expected guidance primarily to challenges affecting the screening segment.
While these explanations are logical, they raise questions about why certain factors weren&#8217;t identified or addressed sooner. Management, however, took full responsibility and conveyed a sincere commitment to improving performance, the analyst writes.
Despite these hurdles, the analyst remains optimistic about revenue growth in 2025, highlighting several factors within the company&#8217;s control.
William Blair emphasizes that investors will likely want to see clear signs of improved execution and revenue growth resuming in 2025.
With shares trading down, the analyst writes that valuation is at a compelling long-term entry point.
Price Action: At last check on Wednesday, EXAS stock was down 28.50% at $51.16.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41753865/apollos-fee-related-earnings-growth-sets-it-apart-in-alternative-assets-says-goldma" target="_blank" rel="noreferrer noopener">Apollo&#8217;s Fee-Related Earnings Growth Sets It Apart in Alternative Assets, Says Goldman Sachs With Bullish EPS Forecast</a></li>
</ul>

Analyst Color

Earnings

Guidance

Health Care

Trading Ideas

General

Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point

Craig-Hallum analyst Alex Nowark maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $82 to $65.

Craig-Hallum Maintains Buy on Exact Sciences, Lowers Price Target to $65

Benchmark analyst Bruce Jackson maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $67 to $65.

Benchmark Maintains Buy on Exact Sciences, Lowers Price Target to $65

U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday.
Shares of Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 revenue <a href="https://www.benzinga.com/general/biotech/24/11/41760212/exact-sciences-stock-plummets-after-worse-than-expected-q3-results-fy24-guidance-below-estimates">guidance below estimates</a>.
Exact Sciences reported quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million missed the consensus estimate of $717.66 million.
Exact Sciences shares dipped 27% to $52.20 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) fell 24.3% to $20.97 in pre-market trading after the company lowered its financial outlook. The company expects to report first-quarter revenue of $5.9 billion to $6 billion, down from its previous guidance range of $6 billion to $7 billion. The company anticipates adjusted earnings of 75 cents to 76 cents per share, versus its previous guidance of 67 cents to 83 cents per share.</li>
<li>Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) fell 20.8% to $1.86 in today's pre-market trading.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) fell 20.1% to $5.64 in pre-market trading after gaining 8% on Tuesday.</li>
<li>PACS Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares fell 18.8% to $24.00 in pre-market trading after the company announced postponement of third-quarter results and disclosure on civil investigative demands from the federal government.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) fell 18.6% to $13.76 in pre-market trading after gaining 5% on Tuesday.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) declined 16.8% to $3.81 in pre-market trading following weak quarterly results.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) shares fell 16.8% to $15.25 in pre-market trading.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) shares fell 14.7% to $184.00 in pre-market trading.</li>
<li>The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) declined 9.9% to $13.97 in pre-market trading.</li>
<li>Honda Motor Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) shares fell 7.4% to $28.05 in pre-market trading as the company said profits fell around 20% in the first half of the fiscal year.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

FSLR

GEVO

NOVA

OSCR

SMCI

Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

WIIM

Exact Sciences shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 revenue guidance below estimates.

Baird analyst Catherine Schulte maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Outperform and lowers the price target from $70 to $67.

Baird Maintains Outperform on Exact Sciences, Lowers Price Target to $67

<h3>Gainers</h3>
<ul>
<li>Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) stock increased by 16.6% to $10.4 during Wednesday's pre-market session. The market value of their outstanding shares is at $514.0 million. As per the press release, Q3 earnings came out today. </li>
<li>Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) shares increased by 15.83% to $6.0. The market value of their outstanding shares is at $642.8 million. </li>
<li>Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) shares increased by 15.11% to $4.34. The company's market cap stands at $272.2 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Xylo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XYLO#NASDAQ">XYLO</a>) stock rose 14.4% to $3.97. The market value of their outstanding shares is at $7.5 million. </li>
<li>Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) shares moved upwards by 13.77% to $85.99. The market value of their outstanding shares is at $11.6 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock increased by 13.63% to $1.25. The company's market cap stands at $4.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock decreased by 26.6% to $52.5 during Wednesday's pre-market session. The company's market cap stands at $9.7 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares declined by 24.53% to $0.1. The company's market cap stands at $1.7 million. </li>
<li>Altamira Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) stock declined by 21.16% to $0.41. The market value of their outstanding shares is at $1.5 million. </li>
<li>PACS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares decreased by 20.49% to $23.49. The market value of their outstanding shares is at $3.6 billion. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock fell 19.66% to $3.68. The company's market cap stands at $1.3 billion. As per the press release, Q3 earnings came out today. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares declined by 15.93% to $0.41. The market value of their outstanding shares is at $5.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNOX

CYTO

GMED

MGNX

PCSA

RGNX

XYLO

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose sharply in today's pre-market trading over a likely Donald Trump victory in the <a href="https://www.benzinga.com/markets/equities/24/11/41767527/tesla-stock-surges-over-13-in-premarket-what-is-going-on">U.S. Presidential elections</a>.
According to The New York Times, Trump currently has over 95% chance of victory given he already has 267 of the 270 electoral votes needed to win. Tesla CEO Elon Musk endorsed Trump in July and has been actively campaigning for the former President both offline and online. Musk even campaigned for Trump in the swing state of Pennsylvania in October.
Tesla shares rose 14% to $286.57 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>FOXO Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NYSE">FOXO</a>) gained 117% to $0.2954 in pre-market trading. FOXO Technologies, last month, said its interim CFO wrote to shareholders expectations to build the business over the next 12-24 months and generate more than $50 million a year in revenue.</li>
<li>ARB IOT Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) rose 93.1% to $1.09 in pre-market trading after the company signed a MOU to accelerate AI with advanced server solutions.</li>
<li>The GEO Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) shares surged 30.7% to $19.78 in pre-market trading after gaining around 7% on Tuesday.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) gained 26.6% to $42.98 in pre-market trading.</li>
<li>DatChat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>) climbed 25.8% to $2.25 in pre-market trading.</li>
<li>Qualys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) shares rose 22.4% to $156.96 in pre-market trading after the company reported better-than-expected third-quarter financial results, raised its FY24 guidance, and issued fourth-quarter revenue guidance above estimates.</li>
<li>Destiny Tech100 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NASDAQ">DXYZ</a>) gained 22.4% to $14.20 in pre-market trading after gaining 6% on Tuesday.</li>
<li>CoreCivic, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXW#NYSE">CXW</a>) gained 21.1% to $16.50 in pre-market trading. CoreCivic will release its third quarter financial results after the closing bell on Wednesday, Nov. 6.</li>
<li>Phunware, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) gained 19.6% to $7.62 in pre-market trading after declining around 8% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares tumbled 55.8% to $2.37 in pre-market trading after dipping more than 20% on Tuesday.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) shares fell 42.5% to $7.56 in pre-market trading after the company announced the pricing of $9.15 million private placement.</li>
<li>Li-Cycle Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LICY#NYSE">LICY</a>) dipped 27.6% to $2.75 in pre-market trading. Li-Cycle to host third quarter earnings conference call/webcast on Thursday, Nov. 7.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) shares fell 27% to $52.20 in pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Simpple Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) declined 27% to $1.23 in pre-market trading. Simpple shares jumped 43% on Tuesday after the company announced its plan to regain NASDAQ compliance.</li>
<li>Bluejay Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares dipped 25.9% to $0.1015 in pre-market trading after gaining 88% on Tuesday.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) fell 24.3% to $20.97 in pre-market trading after the company lowered its financial outlook. The company expects to report first-quarter revenue of $5.9 billion to $6 billion, down from its previous guidance range of $6 billion to $7 billion. The company anticipates adjusted earnings of 75 cents to 76 cents per share, versus its previous guidance of 67 cents to 83 cents per share.</li>
<li>Bionomics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) fell 22.8% to $0.3806 in pre-market trading. Bionomics shares jumped 157% on Tuesday after the company announced it secured an AUS$1 million milestone payment from Carina Biotech for its BNC101 oncology program, with the potential to earn up to AUS$118 million.</li>
<li>Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) fell 20.8% to $1.86 in today's pre-market trading.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) fell 20.1% to $5.64 in pre-market trading after gaining 8% on Tuesday.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

ARBB

DATS

DXYZ

FOXO

LICY

PHUN

QLYS

SPPL

TSLA

VSTE

ZCAR

Why Tesla Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) shares are dropping after the company reported its third-quarter results after Tuesday's closing bell. Here's a <a href="https://www.benzinga.com/pressreleases/24/11/b41757648/exact-sciences-announces-third-quarter-2024-results">look at the details.  </a>
The Details: Exact Sciences reported quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million missed the consensus estimate of $717.66 million.
&#8220;The Exact Sciences&#8217; team is helping eradicate cancer while strengthening our platform and growing our business efficiently,&#8221; said Kevin Conroy, CEO of Exact Sciences. 
&#8220;During the third quarter, we delivered test results to more patients than ever before, improved profitability, and achieved key milestones in our pipeline of innovative cancer diagnostics. While we have made progress, our execution during the third quarter and updated outlook for the full year don&#8217;t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong,&#8221; Conroy added. 
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41715442/trump-media-stock-volatile-on-election-eve-as-polls-betting-markets-predict-tight-white-ho">Trump Media Stock Volatile On Election Eve As Polls, Betting Markets Predict Tight White House Race</a>
Outlook:&nbsp;Exact Sciences sees fiscal year 2024 total revenue in a range of $2.73 billion to $2.75 billion, below the $2.83 billion estimate. 
EXAS Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Exact Sciences shares are down 27.98% after-hours at $51.50 at the time of publication Tuesday.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41719896/alibaba-layoffs-hit-metaverse-division-will-the-chinese-e-commerce-giant-double-down-on-ai">Alibaba Layoffs Hit Metaverse Division: Will The Chinese E-Commerce Giant Double-Down On AI?&nbsp;</a></li>
</ul>
Photo: Courtesy of Exact Sciences Corporation

Biotech

After-Hours Center

Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates

Exact Sciences Sees FY24 Total Revenue $2.730B-$2.750B Vs $2.832B Est.

Baird analyst Catherine Ramsey Schulte lowered the firm's price target on Exact Sciences (EXAS) to $67 from $70 and keeps an Outperform rating on t...

Exact Sciences price target lowered to $67 from $70 at Baird

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on HCA Healthcare (HCA – Research Report), Exact Scie...

Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Exact Sciences (EXAS) and Crispr Therapeutics AG (CRSP)

Citi lowered the firm's price target on Exact Sciences (EXAS) to $75 from $80 and keeps a Buy rating on the shares post the Q3 report The firm says...

Exact Sciences price target lowered to $75 from $80 at Citi

Stifel lowered the firm's price target on Exact Sciences (EXAS) to $67 from $82 and keeps a Buy rating on the shares. Below-consensus Q3 results an...

Exact Sciences price target lowered to $67 from $82 at Stifel

In a report released today, Bruce Jackson from Benchmark Co. maintained a Buy rating on Exact Sciences (EXAS – Research Report), with a price targe...

Exact Sciences (EXAS) Gets a Buy from Benchmark Co.

Piper Sandler analyst David Westenberg assigned a Buy rating to Exact Sciences (EXAS – Research Report) today and set a price target of $85.00. The...

Piper Sandler Gives a Buy Rating to Exact Sciences (EXAS)

BTIG analyst Mark Massaro lowered the firm's price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares. The compan...

Exact Sciences price target lowered to $65 from $82 at BTIG

Jefferies analyst Tycho Peterson raised the firm's price target on Exact Sciences (EXAS) to $85 from $84 and keeps a Buy rating on the shares. Q3 r...

Exact Sciences price target raised to $85 from $84 at Jefferies

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – CVS Health (CVS) up 12% Vertex (VERX) up 6% I...

Morning Movers: CVS Health surges and ODP sinks following Q3 results

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Trump Media (DJT) jumps after Donald T...

Comments

Exact Sciences

Actualités

Dernières nouvelles pour Exact Sciences (NASDAQ:EXAS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL